Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Autor: | Thomas G. P. Grunewald, Jeffrey A. Toretsky, Sebastian Bauer, Wolfgang Hartmann, Stefan K. Zöllner, Volker Vieth, Uta Dirksen, Yasmin Uhlenbruch, Beate Timmermann, Enrique de Álava, Stéphane Collaud, Heinrich Kovar, James F. Amatruda, Markus Metzler, David S. Shulman, Jendrik Hardes, Arne Streitbürger, Steven G. DuBois |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
medicine.medical_specialty EWSR1-FLI1 Medizin lcsh:Medicine Review Disease Systemic therapy Metastasis chromosomal translocation splicing 03 medical and health sciences 0302 clinical medicine fusion protein medicine Recurrent disease metastasis ddc:610 Intensive care medicine Modalities business.industry lcsh:R Cancer limb salvage General Medicine medicine.disease 030104 developmental biology Diagnosis treatment 030220 oncology & carcinogenesis Sarcoma transcription business ewing sarcoma small round cell sarcoma |
Zdroj: | Journal of Clinical Medicine, Vol 10, Iss 1685, p 1685 (2021) Journal of Clinical Medicine |
ISSN: | 2077-0383 |
Popis: | Ewing sarcoma, a highly aggressive bone and soft-tissue cancer, is considered a prime example of the paradigms of a translocation-positive sarcoma: a genetically rather simple disease with a specific and neomorphic-potential therapeutic target, whose oncogenic role was irrefutably defined decades ago. This is a disease that by definition has micrometastatic disease at diagnosis and a dismal prognosis for patients with macrometastatic or recurrent disease. International collaborations have defined the current standard of care in prospective studies, delivering multiple cycles of systemic therapy combined with local treatment; both are associated with significant morbidity that may result in strong psychological and physical burden for survivors. Nevertheless, the combination of non-directed chemotherapeutics and ever-evolving local modalities nowadays achieve a realistic chance of cure for the majority of patients with Ewing sarcoma. In this review, we focus on the current standard of diagnosis and treatment while attempting to answer some of the most pressing questions in clinical practice. In addition, this review provides scientific answers to clinical phenomena and occasionally defines the resulting translational studies needed to overcome the hurdle of treatment-associated morbidities and, most importantly, non-survival. |
Databáze: | OpenAIRE |
Externí odkaz: |